Croma-Pharma GmbH and Crescita Therapeutics have made exclusive commercialization development license agreement over rights for Pliaglis®
Croma-Pharma GmbH (“Croma”) today reported that it has made into a exclusive commercialization development license agreement with Crescita Therapeutics (TSX:
Read more